These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 22998609

  • 1. Enteric-coated mycophenolate sodium in psoriasis vulgaris: an open pilot study.
    Fallah Arani S, Waalboer Spuij R, Nijsten T, Neumann HA, Thio B.
    J Dermatolog Treat; 2014 Feb; 25(1):46-9. PubMed ID: 22998609
    [Abstract] [Full Text] [Related]

  • 2. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
    Ortega F, Sánchez-Fructuoso A, Cruzado JM, Gómez-Alamillo JC, Alarcón A, Pallardó L, Morales JM, Oliver J, Guinea G, MYVIDA Study Group.
    Transplantation; 2011 Aug 27; 92(4):426-32. PubMed ID: 21760569
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bilodeau JF, Montambault P, Wolff JL, Lemire J, Masse M.
    Transplant Proc; 2009 Nov 27; 41(9):3683-9. PubMed ID: 19917367
    [Abstract] [Full Text] [Related]

  • 4. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients.
    Geilen CC, Arnold M, Orfanos CE.
    Br J Dermatol; 2001 Mar 27; 144(3):583-6. PubMed ID: 11260019
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. First experience with enteric-coated mycophenolate sodium (Myfortic) in severe recalcitrant adult atopic dermatitis: an open label study.
    van Velsen SG, Haeck IM, Bruijnzeel-Koomen CA, de Bruin-Weller MS.
    Br J Dermatol; 2009 Mar 27; 160(3):687-91. PubMed ID: 19120337
    [Abstract] [Full Text] [Related]

  • 9. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study.
    Kobashigawa JA, Renlund DG, Gerosa G, Almenar L, Eisen HJ, Keogh AM, Lehmkuhl HB, Livi U, Ross H, Segovia J, Yonan N, ERL2401 Heart Study Investigators.
    J Heart Lung Transplant; 2006 Aug 27; 25(8):935-41. PubMed ID: 16890114
    [Abstract] [Full Text] [Related]

  • 10. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, Neumayer HH.
    Transplant Proc; 2004 Mar 27; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of enteric-coated mycophenolate sodium in patients with de novo and maintenance renal transplantation.
    Qin Y, Zhang F, Shen B, Liu Y, Qiu J, Guo Y, Fan Y.
    Int J Clin Pract Suppl; 2014 Apr 27; (181):17-22. PubMed ID: 24673715
    [Abstract] [Full Text] [Related]

  • 12. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
    Massari P, Duro-Garcia V, Girón F, Hernández E, Juárez F, Castro C, Toledo M, myPROMS LatAm Study Group.
    Transplant Proc; 2005 Mar 27; 37(2):916-9. PubMed ID: 15848574
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study.
    Budde K, Knoll G, Curtis J, Kahana L, Pohanka E, Seifu Y, Neumayer HH.
    Transplant Proc; 2005 Mar 27; 37(2):912-5. PubMed ID: 15848573
    [Abstract] [Full Text] [Related]

  • 14. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study.
    Abbud-Filho M, Girón F, Hernández E, Juarez F, Liendo C, Novoa P, Toledo M, Myproms Latam Study Group.
    Transplant Proc; 2004 Mar 27; 36(6):1647-9. PubMed ID: 15350440
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of tolerance and safety of conversion from mycophenolate mofetil to enteric-coated mycophenolic acid in renal transplant recipients.
    Qiao LW, Qu QS, Jiang X.
    J Biol Regul Homeost Agents; 2017 Mar 27; 31(1):141-146. PubMed ID: 28337883
    [Abstract] [Full Text] [Related]

  • 16. Use of enteric-coated mycophenolate sodium in liver transplant patients with intestinal intolerance caused by mycophenolate mofetil.
    Doria C, Ramirez CB, Frank AM, Vaccino S, Fraser N, Marino IR.
    Clin Transplant; 2009 Mar 27; 23(6):882-6. PubMed ID: 19573090
    [Abstract] [Full Text] [Related]

  • 17. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
    Nashan B, Suwelack B, Ivens K, Arns W, Lhotta K, Bourbigot B, Budde K, Fischer W, Pietruck F, ERL2405-DE02 Study Group.
    Transplant Proc; 2006 Nov 27; 38(9):2856-9. PubMed ID: 17112848
    [Abstract] [Full Text] [Related]

  • 18. Enteric-coated mycophenolate sodium as a corticosteroid-sparing agent for the treatment of autoimmune scleritis.
    Hwang YS, Chen HC, Chen KJ, Lai CC, Yeung L, Yang KJ, Lin KK, Hsiao CH.
    Cornea; 2011 Mar 27; 30(3):260-4. PubMed ID: 21099416
    [Abstract] [Full Text] [Related]

  • 19. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin.
    Pedraz J, Daudén E, Delgado-Jiménez Y, García-Río I, García-Díez A.
    J Eur Acad Dermatol Venereol; 2006 Jul 27; 20(6):702-6. PubMed ID: 16836499
    [Abstract] [Full Text] [Related]

  • 20. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients.
    Salvadori M, Holzer H, Civati G, Sollinger H, Lien B, Tomlanovich S, Bertoni E, Seifu Y, Marrast AC, ERL B301 Study Group.
    Clin Nephrol; 2006 Aug 27; 66(2):112-9. PubMed ID: 16939067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.